ArticleJournal of gynecologic oncology2023
Risk factors for lower extremity lymphedema after surgery in cervical and endometrial cancer.
Article in Journal of gynecologic oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05421650 (Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr: A Phase III, Randomized Controlled Clinical Trial
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Risk factors for lower limb lymphedema after gynecological cancer treatment: a systematic review.Frontiers in oncology · 2025Pooled it
- Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial.Journal of gynecologic oncology · 2024Trial
- Best Evidence for the Exercise-Based Management of Lower Limb Lymphedema After Gynecological Cancer: A Systematic Review and Evidence Synthesis.Journal of multidisciplinary healthcare · 2026Review
- A prospective assessment of simple lymphatic drainage to prevent lower limb lymphedema in gynecological malignancies.Scientific reports · 2025Article
- Lower extremity lymphedema after pelvic nodal dissection for urologic cancers is associated with metastatic recurrence.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- A 5-year prospective assessment of risk factors for lower limb lymphedema after gynecologic cancer surgery.Scientific reports · 2025Article
- Prevalence of lymphedema symptoms across cancer diagnoses and association with depression, pain interference and health-related quality of life.Acta oncologica (Stockholm, Sweden) · 2025Article
- Analysis of Risk Factors of Lymphedema After Surgical Treatment in Cervical Cancer: A Case-Control Retrospective Study.International journal of general medicine · 2025Article
- Construction of a nomogram for personalized prediction of lower limb lymphedema risk after cervical cancer surgery.BMC women's health · 2024Article
- Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLower extremity lymphedema (LEL) is a well-known adverse effect related to cervical and endometrial cancer (CEC); however, very few studies have elucidated the clinicopathologic risk factors related to LEL. We investigated the incidence and risk factors in patients who received primary surgery and/or adjuvant radiotherapy (RT) or chemotherapy for CEC.
methodsWe retrospectively reviewed 2,565 patients who underwent primary surgery following CEC diagnosis between January 2007 and December 2020. LEL diagnosis was based on objective and subjective assessments by experts. We identified important predictors of LEL to construct a nomogram predicting individual risks of LEL. For internal validation of the nomogram, the original data were separated using the split-sample method in a 7:3 ratio of training data and test data.
resultsOverall, 858 patients (33.5%) received RT, 586 received external beam RT (EBRT), and 630 received intracavitary RT. During follow-up period, LEL developed in 331 patients, with an overall cumulative 5-year incidence of 13.3%. In multivariate analysis, age at primary treatment, use of docetaxel-based chemotherapy, type of hysterectomy, type of surgical pelvic lymph node (LN) assessment, number of dissected pelvic and para-aortic LNs, and EBRT field were the independent predictors of LEL. We subsequently developed the nomogram showing excellent predictive power for LEL.
conclusionLEL is associated with various treatment modalities, and their interactions may increase the possibility of occurrences. De-escalation strategies for treatment modalities should be considered to reduce LEL in patients with CEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.